1. 73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study. (17th December 2018) Authors: He, A R; Weiss, G J; Falchook, G; Yee, N S; Gil-Martin, M; Shahda, S; Moreno, V; Brana, I; Crittenden, M; Formenti, S; Al-Rajabi, R; Papadopoulos, K P; Pishvaian, M J; Stankevich, E; Feng, M; Li, J; Mathias, M; Kroog, G; Lowy, I; Fury, M G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 75PCemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts. (17th December 2018) Authors: Rischin, D; Gil-Martin, M; González-Martin, A; Brana, I; Hou, J Y; Cho, D; Falchook, G; Formenti, S; Jabbour, S; Moore, K; Naing, A; Papadopoulos, K P; Baranda, J; Weise, A; Fury, M G; Feng, M; Li, J; Lowy, I; Mathias, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗